Valentı́n Fuster works in General / Preventive / Lipids affiliated with Mount Sinai Hospital.
Valentin Fuster, MD, PhD, is President of Mount Sinai Fuster Heart Hospital and Physician-in-Chief of The Mount Sinai Hospital. He also serves as General Director of the Spanish National Centre for Cardiovascular Research (CNIC) in Madrid. He previously was Mallinckrodt Professor of Medicine at Harvard Medical School and Chief of Cardiology at Massachusetts General Hospital from 1991 to 1994.
2,202 pubs · 248,499 cites · h-index 218
MD
Universidad de Barcelona
1967
PhD
University of Edinburgh
1971
President of Mount Sinai Fuster Heart Hospital and Physician-in-Chief
The Mount Sinai Hospital / Mount Sinai Health System · 2012 - Present
General Director
Spanish National Centre for Cardiovascular Research (CNIC) · 2006 - Present
Director, Zena and Michael A. Wiener Cardiovascular Institute
Icahn School of Medicine at Mount Sinai · 1994 - Present
Mallinckrodt Professor of Medicine and Chief of Cardiology
Harvard Medical School / Massachusetts General Hospital · 1991 - 1994
Professor of Medicine and Consultant in Cardiology
Mayo Clinic / Mayo Medical School · 1974 - 1981
JACCSack et al.review
This comprehensive review details the fundamental biological mechanisms connecting mitochondrial reactive oxygen species, programmed cell death, telomere attrition, and cellular senescence to the pathogenesis of cardiovascular disease.
Interventional / Structural Cardiology · Instituto de Salud Carlos III
The next step is to determine whether strategies to reduce inflammation can help halt the atherosclerotic process. Previous clinical trials in this area generated controversial results, but they were conducted in the context of much more advanced atherosclerosis. Targeting inflammation at earlier stages may turn out to be more beneficial than later interventions, although this is something we need to test.
European Heart JournalMendieta et al.
JACCLai et al.review
May aid personalized risk stratification in hemodialysis patients; extends observational data but leaves open prospective validation.
JACCRoolvink et al.RCT
Early IV metoprolol before PPCI does not reduce infarct size in STEMI; challenges routine prehospital use and prior smaller studies.
Interventional / Structural Cardiology · Cedars-Sinai Smidt Heart Institute
Our study report supports the use of CABG surgery over PCT; however the results should not be overly simplified. The management of patients with diabetes and coronary disease should still be personalized to include an assessment of surgical risk and benefits as well as patient preferences.
Journal of the American College of CardiologyFarkouh et al.
Interventional / Structural Cardiology · Instituto de Salud Carlos III
conventional risk factors (blood cholesterol, hypertension, smoking, etc.) allow a broad prediction of the population risk of severe cardiovascular events (infarction or stroke); however, individualized predictions based on these risk factors are not very accurate. Now, with the ability to directly visualize atherosclerotic plaques and quantify their number and size in the body, we will be able to predict risk more accurately. The presence and extent of atherosclerosis gives direct information about how risk factors affect the arteries in each individual.
Journal of the American College of CardiologyLópez‐Melgar et al.
JACCRudd et al.review
FDG-PET may refine inflammation-based risk assessment; leaves open routine clinical adoption pending prospective validation.
Interventional / Structural Cardiology · Cedars-Sinai Smidt Heart Institute
We tried to look at the predictors of who had a better outcome, and in the bypass patients the SYNTAX score really didn't make much difference. The SYNTAX score didn't drive outcomes. It did somewhat in the PCI group, but not in the comparison with PCI versus CABG. It had only a modest impact. So what this tells us if we're going to make a decision to perform PCI or CABG, the SYNTAX shouldn't be driving the decision.
Journal of the American College of CardiologyÉsper et al.
Interventional / Structural Cardiology · Piedmont Atlanta Hospital
this is the largest sham-controlled, randomized experience we have with this method of renal denervation, and it confirms the biologic proof of principle or the efficacy of renal denervation to reduce blood pressure
The LancetBöhm et al.
Heart Failure Treatment and Management · Massachusetts College of Pharmacy and Health Sciences
The new guidelines help to establish the type of patient population for which the drug is best suited. Dofetilide is one of the few drugs that can be used in heart failure patients.
Journal of the American College of CardiologyFuster et al.
JACCRudd et al.cohort
FDG-PET/CT demonstrates high short-term reproducibility and observer agreement for measuring atherosclerotic plaque inflammation in the carotid arteries and aorta, supporting its utility as a surrogate endpoint in clinical trials of antiatheroma therapies.
JACCHeymans et al.Original Research
May prompt enhanced myocarditis surveillance after mRNA-1273 in youth; leaves open need for prospective causal confirmation.
JACCFusterOriginal Research
JACCAgüero et al.preclinical
Aerosolized AAV1.SERCA2a showed efficacy in swine post-capillary PH; leaves open translation to human trials.
Interventional Cardiology · Centre Hospitalier de Luxembourg
Previous trials have provided evidence for SGLT-2 inhibitors in patients with a variety of other conditions but have excluded patients with valvular heart disease. Based on our study, if you have a patient undergoing TAVI who is at risk of heart failure, it is important to treat them with dapagliflozin or another SGLT-2 inhibitor. These are safe drugs and have a lot of benefit.
Journal of the American Heart AssociationManzanares et al.
JACCBeerkens et al.cohort
AIP trajectories should not guide post-TAVR risk stratification; leaves open metabolic phenotype effects in prospective studies.
General Cardiology · Universitat Autònoma de Barcelona
Our findings extend the known benefits of these agents in MI patients with reduced LVEF to the subgroup with mildly reduced LVEF. Further research should now focus on patients with preserved LVEF (>50%).
The LancetRosselló et al.
AtherosclerosisGarcía‐Álvarez et al.Original Research
Cardiologist; General Director, CNIC, Madrid · Centro Nacional de Investigaciones Cardiovasculares (CNIC) / Mount Sinai
There is a need for a complete change in the timing of when we deliver care. Until now, the clinical community has focused on cardiovascular disease, which typically manifests in the later stages of life. Now, we need to focus our care in the opposite stage of life--we need start promoting health at the earliest years, as early as 3 to 5 years old, in order to prevent cardiovascular disease.
Journal of the American College of CardiologyPeñalvo et al.
